ES2980811T3 - Derivados de pirrolotriazina para el tratamiento de enfermedades mediadas por KIT y PDGFRA - Google Patents

Derivados de pirrolotriazina para el tratamiento de enfermedades mediadas por KIT y PDGFRA Download PDF

Info

Publication number
ES2980811T3
ES2980811T3 ES20721083T ES20721083T ES2980811T3 ES 2980811 T3 ES2980811 T3 ES 2980811T3 ES 20721083 T ES20721083 T ES 20721083T ES 20721083 T ES20721083 T ES 20721083T ES 2980811 T3 ES2980811 T3 ES 2980811T3
Authority
ES
Spain
Prior art keywords
compound
chosen
mmol
pharmaceutically acceptable
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20721083T
Other languages
English (en)
Spanish (es)
Inventor
Joseph Kim
Thomas Dineen
Timothy Guzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blueprint Medicines Corp
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70416596&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2980811(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Application granted granted Critical
Publication of ES2980811T3 publication Critical patent/ES2980811T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES20721083T 2019-04-12 2020-04-08 Derivados de pirrolotriazina para el tratamiento de enfermedades mediadas por KIT y PDGFRA Active ES2980811T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962833529P 2019-04-12 2019-04-12
US201962911016P 2019-10-04 2019-10-04
US201962930240P 2019-11-04 2019-11-04
PCT/US2020/027177 WO2020210293A1 (en) 2019-04-12 2020-04-08 Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases

Publications (1)

Publication Number Publication Date
ES2980811T3 true ES2980811T3 (es) 2024-10-03

Family

ID=70416596

Family Applications (1)

Application Number Title Priority Date Filing Date
ES20721083T Active ES2980811T3 (es) 2019-04-12 2020-04-08 Derivados de pirrolotriazina para el tratamiento de enfermedades mediadas por KIT y PDGFRA

Country Status (33)

Country Link
US (2) US12552795B2 (https=)
EP (2) EP4424312A3 (https=)
JP (2) JP7600140B2 (https=)
KR (1) KR102875260B1 (https=)
CN (1) CN113939515B (https=)
AU (1) AU2020272743B2 (https=)
BR (1) BR112021020441A2 (https=)
CA (1) CA3136802A1 (https=)
CL (1) CL2021002656A1 (https=)
CO (1) CO2021015113A2 (https=)
DK (1) DK3953357T3 (https=)
EC (1) ECSP21080096A (https=)
ES (1) ES2980811T3 (https=)
FI (1) FI3953357T3 (https=)
HR (1) HRP20240702T1 (https=)
HU (1) HUE067299T2 (https=)
IL (1) IL287168B2 (https=)
LT (1) LT3953357T (https=)
MA (1) MA55604B1 (https=)
MD (1) MD3953357T2 (https=)
MX (1) MX2021012469A (https=)
MY (1) MY209048A (https=)
PE (1) PE20212331A1 (https=)
PH (1) PH12021552568A1 (https=)
PL (1) PL3953357T3 (https=)
PT (1) PT3953357T (https=)
RS (1) RS65644B1 (https=)
SG (1) SG11202111244XA (https=)
SI (1) SI3953357T1 (https=)
SM (1) SMT202400229T1 (https=)
TW (1) TWI857043B (https=)
WO (1) WO2020210293A1 (https=)
ZA (1) ZA202108104B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109970745B (zh) 2018-04-16 2020-12-08 深圳市塔吉瑞生物医药有限公司 取代的吡咯并三嗪类化合物及其药物组合物及其用途
BR112021020441A2 (pt) * 2019-04-12 2021-12-14 Blueprint Medicines Corp Derivados de pirrolotriazina para tratar doenças mediadas por kit e pdgfra
US20230391780A1 (en) * 2020-10-14 2023-12-07 Blueprint Medicines Corporation Compositions and methods for treating kit- and pdgfra-mediated diseases
US20240010652A1 (en) * 2020-10-14 2024-01-11 Blueprint Medicines Corporation Compositions and methods for treating kit- and pdgfra-mediated diseases
HU231413B1 (hu) 2021-02-26 2023-08-28 Egis Gyógyszergyár Zrt. Eljárás avapritinib és intermedierek előállítására
AU2022231009A1 (en) * 2021-03-03 2023-09-21 Blueprint Medicines Corporation Synthetic methods and intermediates for producing compounds for treating kit- and pdgfra-mediated diseases
CN117794935A (zh) * 2021-03-10 2024-03-29 缆图药品公司 激酶抑制剂的盐和固体形式
JP2024509276A (ja) * 2021-03-10 2024-02-29 ブループリント メディシンズ コーポレイション キナーゼ阻害剤の塩及び固体形態
CN113278023B (zh) * 2021-07-22 2021-10-15 上海睿跃生物科技有限公司 含氮杂环化合物及其制备方法和应用
AU2022379973A1 (en) * 2021-11-08 2024-06-27 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2024171143A1 (en) 2023-02-17 2024-08-22 Assia Chemical Industries Ltd. Salts and solid forms of elenestinib

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61238784A (ja) 1985-04-17 1986-10-24 Sumitomo Seiyaku Kk コハク酸イミド誘導体及びその酸付加塩
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
JP4649046B2 (ja) 1999-05-21 2011-03-09 ブリストル−マイヤーズ スクイブ カンパニー キナーゼのピロロトリアジン阻害剤
MXPA02003436A (es) 1999-10-07 2002-08-20 Amgen Inc Inhibidores de triazina cinasa.
SE0102616D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
PT1497019E (pt) 2002-04-23 2015-09-10 Bristol Myers Squibb Co Compostos de pirrolotriazina anilina úteis como inibidores de quinase
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
US7468376B2 (en) 2003-02-27 2008-12-23 Palau Pharma, S.A. Pyrazolopyridine derivates
MY145634A (en) 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
WO2006028524A2 (en) 2004-04-29 2006-03-16 Pharmix Corporation Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JP5116687B2 (ja) 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
DK1973910T3 (da) 2006-01-27 2013-08-12 Shanghai Hengrui Pharm Co Ltd Pyrrolo[3,2-c]pyridin-4-on-2-indolinon-proteinkinaseinhibitorer
HRP20140688T1 (hr) 2006-07-07 2014-10-24 Bristol-Myers Squibb Company Inhibitori piroltriazin kinaze
US8415340B2 (en) 2007-07-25 2013-04-09 Bristol-Myers Squibb Company Triazine kinase inhibitors
CA2716856C (en) 2008-03-20 2013-02-19 Amgen Inc. Aurora kinase modulators and method of use
WO2010022055A2 (en) 2008-08-20 2010-02-25 Amgen Inc. Inhibitors of voltage-gated sodium channels
JP2012529512A (ja) 2009-06-08 2012-11-22 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー トリアジン誘導体類及びそれらの治療応用
CA2767008C (en) 2009-07-07 2018-01-30 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
WO2011103196A1 (en) 2010-02-17 2011-08-25 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
CN102040494A (zh) 2010-11-12 2011-05-04 西北师范大学 对氟苯甲醛的制备方法
SG195100A1 (en) 2011-07-01 2013-12-30 Bayer Ip Gmbh Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
EP2892534B8 (en) 2012-09-06 2021-09-15 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
MX365640B (es) 2012-12-21 2019-06-10 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas y sus indicaciones.
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
WO2015058129A1 (en) 2013-10-17 2015-04-23 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
SI3057969T1 (sl) 2013-10-17 2018-10-30 Blueprint Medicines Corporation Sestavki, uporabni za zdravljenje motenj, povezanih s KIT
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
CN108026102A (zh) 2015-07-24 2018-05-11 蓝印药品公司 可用于治疗与kit和pdgfr相关的病症的化合物
SI3371171T1 (sl) 2015-11-02 2024-03-29 Blueprint Medicines Corporation Inhibitorji ret
AR110963A1 (es) 2017-02-07 2019-05-22 Dae Woong Pharma Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende
KR102398659B1 (ko) 2017-03-17 2022-05-16 주식회사 대웅제약 카이네이즈 저해제로서의 피롤로트리아진 유도체
US11040979B2 (en) 2017-03-31 2021-06-22 Blueprint Medicines Corporation Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
CN109400610A (zh) 2017-08-18 2019-03-01 浙江海正药业股份有限公司 吡咯并三嗪类衍生物、其制备方法及其在医药上的用途
CN108191874B (zh) 2018-01-16 2019-11-29 成都施贝康生物医药科技有限公司 一种C-Kit抑制剂及其应用
CN109970745B (zh) 2018-04-16 2020-12-08 深圳市塔吉瑞生物医药有限公司 取代的吡咯并三嗪类化合物及其药物组合物及其用途
CR20200588A (es) 2018-05-04 2021-06-24 Inflazome Ltd Compuestos novedosos
US20220010382A1 (en) 2018-11-12 2022-01-13 Blueprint Medicines Corporation Avapritinib resistance of kit mutants
MA54526A (fr) 2018-12-20 2022-03-30 Pfizer NOUVELLES FORMES POLYMORPHES D'UN INHIBITEUR DE TGFBeta
BR112021020441A2 (pt) * 2019-04-12 2021-12-14 Blueprint Medicines Corp Derivados de pirrolotriazina para tratar doenças mediadas por kit e pdgfra
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
CN110938077B (zh) 2019-12-25 2021-04-27 武汉九州钰民医药科技有限公司 合成Avapritinib的方法
CN110950872A (zh) 2019-12-25 2020-04-03 武汉九州钰民医药科技有限公司 制备靶向抗癌药avapritinib的方法
US20230391780A1 (en) 2020-10-14 2023-12-07 Blueprint Medicines Corporation Compositions and methods for treating kit- and pdgfra-mediated diseases

Also Published As

Publication number Publication date
US20220153748A1 (en) 2022-05-19
ZA202108104B (en) 2024-02-28
US12552795B2 (en) 2026-02-17
US20200325141A1 (en) 2020-10-15
JP7600140B2 (ja) 2024-12-16
JP2025029094A (ja) 2025-03-05
IL287168A (en) 2021-12-01
WO2020210293A1 (en) 2020-10-15
CL2021002656A1 (es) 2022-08-26
CN113939515A (zh) 2022-01-14
PL3953357T3 (pl) 2024-09-02
CA3136802A1 (en) 2020-10-15
EP4424312A3 (en) 2025-01-08
FI3953357T3 (fi) 2024-07-15
EP3953357A1 (en) 2022-02-16
BR112021020441A2 (pt) 2021-12-14
CO2021015113A2 (es) 2022-02-28
EP3953357B1 (en) 2024-04-17
TWI857043B (zh) 2024-10-01
MY209048A (en) 2025-06-18
KR20220025704A (ko) 2022-03-03
SI3953357T1 (sl) 2024-08-30
ECSP21080096A (es) 2022-02-25
US10829493B2 (en) 2020-11-10
TW202104231A (zh) 2021-02-01
AU2020272743B2 (en) 2025-10-16
HRP20240702T1 (hr) 2024-08-16
DK3953357T3 (en) 2024-06-10
PH12021552568A1 (en) 2022-07-04
JP2022526850A (ja) 2022-05-26
PT3953357T (pt) 2024-07-24
MA55604A (fr) 2022-02-16
IL287168B1 (en) 2025-06-01
SMT202400229T1 (it) 2024-07-09
PE20212331A1 (es) 2021-12-14
RS65644B1 (sr) 2024-07-31
AU2020272743A1 (en) 2021-11-11
HUE067299T2 (hu) 2024-10-28
MD3953357T2 (ro) 2024-09-30
SG11202111244XA (en) 2021-11-29
KR102875260B1 (ko) 2025-10-23
MA55604B1 (fr) 2024-08-30
CN113939515B (zh) 2024-06-18
EP4424312A2 (en) 2024-09-04
IL287168B2 (en) 2025-10-01
LT3953357T (lt) 2024-07-25
MX2021012469A (es) 2022-01-18

Similar Documents

Publication Publication Date Title
ES2980811T3 (es) Derivados de pirrolotriazina para el tratamiento de enfermedades mediadas por KIT y PDGFRA
EP2960238B1 (en) Monocyclic pyridine derivative
CN118307563A (zh) 一种多环化合物及其制备方法和用途
EA021817B1 (ru) Кристаллический (r)-(e)-2-(4-(2-(5-(1-(3,5-дихлорпиридин-4-ил)этокси)-1h-индазол-3-ил)винил)-1h-пиразол-1-ил)этанола моногидрат
AU2018208231A1 (en) Imidazopyrazine compound, preparation method therefor and use thereof
CN117098760B (zh) 用于治疗kit和pdgfra介导的疾病的组合物和方法
US20240299387A1 (en) Heterocyclic egfr inhibitors for use in the treatment of cancer
US20230391780A1 (en) Compositions and methods for treating kit- and pdgfra-mediated diseases
RU2817354C2 (ru) Композиции и способы лечения kit- и pdgfra-опосредованных заболеваний
HK40071629A (en) Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases
HK40071629B (en) Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases
CN120731212A (zh) 作为egfr抑制剂的大环氨基吡啶化合物
CN122003414A (zh) 作为kras降解剂的取代三环化合物
HK1215949B (en) Monocyclic pyridine derivative
HK1207374B (en) Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
HK1207374A1 (en) Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors